Picton Mahoney Asset Management Has $28.70 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Picton Mahoney Asset Management lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 20.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,226 shares of the company’s stock after selling 12,633 shares during the quarter. Eli Lilly and Company accounts for 0.8% of Picton Mahoney Asset Management’s investment portfolio, making the stock its 10th largest holding. Picton Mahoney Asset Management’s holdings in Eli Lilly and Company were worth $28,695,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of the stock. Lipe & Dalton bought a new position in Eli Lilly and Company in the 4th quarter valued at $26,000. Thompson Investment Management Inc. purchased a new position in shares of Eli Lilly and Company in the third quarter worth $27,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company in the third quarter worth $36,000. Family CFO Inc purchased a new position in shares of Eli Lilly and Company in the third quarter worth $40,000. Finally, O Brien Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 70.5% in the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock worth $44,000 after purchasing an additional 31 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded up $11.09 during mid-day trading on Tuesday, reaching $777.77. The company’s stock had a trading volume of 2,842,407 shares, compared to its average volume of 3,088,457. The firm has a market capitalization of $739.20 billion, a PE ratio of 114.55, a P/E/G ratio of 1.45 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The stock has a fifty day moving average of $761.22 and a two-hundred day moving average of $674.88. Eli Lilly and Company has a 52 week low of $419.80 and a 52 week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.62 earnings per share. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Analyst Ratings Changes

Several research firms have recently weighed in on LLY. The Goldman Sachs Group boosted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price target (up previously from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday, April 30th. Barclays lifted their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Finally, Bank of America lifted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.